Alaska Syndromic Surveillance On-Boarding Process

All Syndromic Surveillance reporting to the Alaska Department of Public Health for Meaningful Use purposes will be reported using the Alaska eHealth Network (AeHN). The state of Alaska uses the CDC surveillance system, BioSense to satisfy Syndromic Surveillance reporting. AeHN, in conjunction with the Alaska Department of Public Health Section of Epidemiology (AKDPH-SOE), has implemented procedures with the BioSense program to streamline Syndromic Surveillance reporting for Alaska hospitals. Syndromic Surveillance reporting is based on the ADT interface that AeHN will be receiving from each hospital. AeHN will implement one interface for ADT messages and will forward messages specific to Syndromic Surveillance reporting to BioSense.

Step	Step Name	Description
1	**Registration / Readiness**	Hospital on-boarding for Syndromic Surveillance reporting must: • Participate / register with AeHN: http://www.ak-ehealth.org/for-providers/join-our-providers/ • Register their Meaningful Use Intent with AKDHSS-MU: http://dhss.alaska.gov/HIT/Meaningfuluse/Pages/Default.aspx Hospital staff will be responsible for reviewing specific Syndromic Surveillance reporting documentation (e.g., Meaningful Use requirements)
2	**AeHN Pre-Implementation**	AeHN staff will work with the hospital to prepare for the sending of live data to BioSense. Pre-Implementation steps include: • Creation of message transaction specifications • Duplicate Patient Management process • Security Assessment • Environmental Considerations o User / Site Administration o Policies (authorization, breach management, monitoring, etc.) o Marketing Plan o Education and Training Plan o Roll Out Plan • LOINC / SNOMED code mapping • AeHN will also verify Syndromic Surveillance messages meet HL7 standards in terms of structure and required fields
3	**In Queue**	If the hospital is ready to submit on-going Syndromic Surveillance data, but BioSense or AeHN have reached on-boarding capacity, the hospital may be placed in a queue for on-going submission and validation. Facilities placed in the queue can still attest for Meaningful Use Stage 2, if that is their goal.
4	**Initial Submission / BioSense Validation**	Once the hospital is ready to generate messages that meet the required standards, live Syndromic Surveillance (production) messages will be sent to BioSense. AeHN and AKDPH-SOE will validate the data within the messages to ensure accuracy, appropriate coding, removal of PHI, etc. AeHN and AKDPH-SOE will ensure your hospital Syndromic Surveillance reporting not only meets Meaningful Use requirements but will assist the hospital in utilizing the data reported to BioSense for outbreak detection, investigations, and community actions.
5	**Production & On-going Validation**	After your Syndromic Surveillance reporting has been validated by AeHN, AKDPH-SOE, and BioSense and a secure method of transfer has been successfully tested, on-going production level data will be transferred from your system on at least a daily basis.